Evidence recordApplied to skin
Trifarotene (prescription topical)
Answer
Two 12-week randomized, double-blind, vehicle-controlled phase 3 trials found greater facial and truncal acne improvement with trifarotene 0.005% cream than vehicle.
Check the formulaEvidence grade
Strong
Several consistent, relevant sources or an authoritative synthesis support this bounded claim.
Where it stops
Trifarotene is a prescription retinoid. Local irritation and ultraviolet-exposure precautions apply. The trial author list included employees of Galderma R&D, the manufacturer's research organization; neither held source compares trifarotene with another retinoid or establishes adjunctive-treatment benefit.
Sources
Sources · 2
Source 1
J Am Acad Dermatol, 2019- Design
- Randomized, double-blind, vehicle-controlled phase 3 trials
- Duration
- 12 weeks
- Reported numbers
- 0.005%
- Measured outcome
- facial acne vulgaris, truncal acne vulgaris
- Studied formulation
- 0.005% trifarotene cream
Finding
Two separate 12-week randomized, double-blind, vehicle-controlled phase 3 trials in patients aged 9 years or older found trifarotene 0.005% cream superior to vehicle on investigator success and inflammatory and non-inflammatory lesion counts on the face and trunk. The author list included employees of Galderma R&D.
- Reported numbers
- 0.005%
- Measured outcome
- U.S. prescribing indication for acne, skin irritation safety, ultraviolet-exposure precautions
- Studied formulation
- 0.005% trifarotene cream
Finding
The current U.S. prescribing information, revised October 2023, indicates topical 0.005% trifarotene cream for acne vulgaris on the face and/or trunk in patients aged 9 years and older, and warns about local irritation and ultraviolet exposure. It does not establish superiority or lower irritation versus another retinoid.